{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:26:40Z","timestamp":1773059200502,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Aortic stenosis (AS) is the most prevalent valve disease in developed countries, with its incidence rising in the aging population. The current criteria for aortic valve replacement (AVR) are based on subjective symptoms and left ventricular ejection fraction (LVEF), which may not adequately reflect left ventricular (LV) dysfunction. This highlights the necessity for objective biomarkers to evaluate subclinical LV dysfunction. Serum angiotensin-converting enzyme 2 (sACE2) has emerged as a promising novel biomarker for cardiovascular diseases. To investigate the association between sACE2 activity and different flow-grade categories of severe AS, compare it with the traditional biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP), and assess the utility of sACE2 as a biomarker for AS. sACE2 and NT-proBNP were measured in 175 patients (97 male, 78 female, mean age 75\u2009\u00b1\u20098\u00a0years) diagnosed with severe AS (aortic valve area, AVA\u2009\u2264\u20091 cm\n                    <jats:sup>2<\/jats:sup>\n                    ). Patients were classified into 5 groups depending on LV flow state and pressure gradient levels: normal flow-low gradient (NF-LG), normal flow-high gradient (NF-HG), low flow-high gradient (LF-HG), low flow-low gradient (LF-LG), and paradoxical low flow-low gradient (PLF-LG) AS. Both biomarkers showed a general increase with advanced stages of severe AS (NF-LG: 65.0\u2009\u00b1\u20093.5 U\/ml; LF-LG: 148.1\u2009\u00b1\u200916.8 U\/ml;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05 for sACE2 and NF-LG: 687\u2009\u00b1\u2009193\u00a0pg\/ml; LF-LG: 5966\u2009\u00b1\u20091076\u00a0pg\/ml;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05 for NT-proBNP). Notably, PLF-LG patients exhibited NT-proBNP levels similar to NF groups (PLF-LG: 1010\u2009\u00b1\u2009218\u00a0pg\/ml). Both biomarkers negatively correlated with LVEF and AVA. Receiver operating characteristic (ROC) analysis revealed that sACE2 provides incremental value over NT-proBNP in detecting subclinical LV dysfunction, with a 44% specificity for sACE2 compared to 6% for NT-proBNP at 98,67% sensitivity. The assessment of sACE2 activity in patients with AS provides valuable insights into disease stage and progression, supporting clinical decision-making and optimizing the timing of AVR. Furthermore, sACE2 activity serves as a moderately sensitive blood biomarker for identifying patients at risk of AS.\n                  <\/jats:p>","DOI":"10.1007\/s11357-025-01792-6","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:32:09Z","timestamp":1752607929000},"page":"2423-2437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum ACE2 activity as a novel biomarker of assessment of severe aortic stenosis"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8815-7158","authenticated-orcid":false,"given":"Anita","family":"Kurczina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold P\u00e9ter","family":"R\u00e1duly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivetta M\u00e1nyin\u00e9","family":"Siket","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"P\u00f3lik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertalan","family":"Kracsk\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila B\u00e9la","family":"Kert\u00e9sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Antal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"\u00d6tv\u00f6s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"Fagyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Szerafin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Csan\u00e1di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Borb\u00e9ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"3","key":"1792_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nrcardio.2010.202","volume":"8","author":"B Iung","year":"2011","unstructured":"Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol. 2011;8(3):162\u201372. https:\/\/doi.org\/10.1038\/nrcardio.2010.202.","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"1792_CR2","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1016\/S2666-7568(22)00168-4","volume":"3","author":"S Stewart","year":"2022","unstructured":"Stewart S, Afoakwah C, Chan Y-K, Strom JB, Playford D, Strange GA. Counting the cost of premature mortality with progressively worse aortic stenosis in Australia: a clinical cohort study. Lancet Healthy Longevity. 2022;3(9):e599\u2013606. https:\/\/doi.org\/10.1016\/S2666-7568(22)00168-4.","journal-title":"Lancet Healthy Longevity"},{"issue":"7","key":"1792_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, et al. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561\u2013632. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395.","journal-title":"Eur Heart J"},{"key":"1792_CR4","doi-asserted-by":"publisher","unstructured":"Otto CM, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5), https:\/\/doi.org\/10.1161\/CIR.0000000000000923.","DOI":"10.1161\/CIR.0000000000000923"},{"issue":"3","key":"1792_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jacc.2011.08.072","volume":"59","author":"P Lancellotti","year":"2012","unstructured":"Lancellotti P, et al. Clinical outcome in asymptomatic severe aortic stenosis. J Am Coll Cardiol. 2012;59(3):235\u201343. https:\/\/doi.org\/10.1016\/j.jacc.2011.08.072.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"1792_CR6","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1161\/01.CIR.0000060533.79248.0C","volume":"107","author":"IL Gerber","year":"2003","unstructured":"Gerber IL, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003;107(14):1884\u201390. https:\/\/doi.org\/10.1161\/01.CIR.0000060533.79248.0C.","journal-title":"Circulation"},{"issue":"19","key":"1792_CR7","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.08.2162","volume":"72","author":"TH Marwick","year":"2018","unstructured":"Marwick TH. Ejection fraction pros and cons. J Am Coll Cardiol. 2018;72(19):2360\u201379. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.2162.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1792_CR8","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jacc.2023.09.796","volume":"82","author":"P G\u00e9n\u00e9reux","year":"2023","unstructured":"G\u00e9n\u00e9reux P, et al. The mortality burden of untreated aortic stenosis. J Am Coll Cardiol. 2023;82(22):2101\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2023.09.796.","journal-title":"J Am Coll Cardiol"},{"key":"1792_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.amjcard.2023.08.001","volume":"206","author":"A Sarkar","year":"2023","unstructured":"Sarkar A, et al. Biomarkers as prognostic markers for aortic stenosis: a review. Am J Cardiol. 2023;206:53\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2023.08.001.","journal-title":"Am J Cardiol"},{"issue":"11","key":"1792_CR10","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/biom13111661","volume":"13","author":"A Dr\u0103gan","year":"2023","unstructured":"Dr\u0103gan A, Mateescu AD. Novel biomarkers and advanced cardiac imaging in aortic stenosis: old and new. Biomolecules. 2023;13(11):1661. https:\/\/doi.org\/10.3390\/biom13111661.","journal-title":"Biomolecules"},{"issue":"2","key":"1792_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1161\/CIRCHEARTFAILURE.114.001649","volume":"8","author":"V Parikh","year":"2015","unstructured":"Parikh V, Kim C, Siegel RJ, Arsanjani R, Rader F. Natriuretic peptides for risk stratification of patients with valvular aortic stenosis. Circ Heart Failure. 2015;8(2):373\u201380. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001649.","journal-title":"Circ Heart Failure"},{"key":"1792_CR12","doi-asserted-by":"publisher","unstructured":"Donoghue M. et al. A novel Angiotensin-Converting Enzyme\u2013Related Carboxypeptidase (ACE2) converts Angiotensin I to Angiotensin 1\u20139. Circ Res 2000;87(5), https:\/\/doi.org\/10.1161\/01.RES.87.5.e1","DOI":"10.1161\/01.RES.87.5.e1"},{"issue":"6","key":"1792_CR13","doi-asserted-by":"publisher","first-page":"H2373","DOI":"10.1152\/ajpheart.00426.2008","volume":"295","author":"PE Gallagher","year":"2008","unstructured":"Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373\u20139. https:\/\/doi.org\/10.1152\/ajpheart.00426.2008.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"20","key":"1792_CR14","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605\u201310. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.510461.","journal-title":"Circulation"},{"issue":"4","key":"1792_CR15","doi-asserted-by":"publisher","first-page":"e87845","DOI":"10.1371\/journal.pone.0087845","volume":"9","author":"K \u00dari","year":"2014","unstructured":"\u00dari K, et al. New perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS ONE. 2014;9(4):e87845. https:\/\/doi.org\/10.1371\/journal.pone.0087845.","journal-title":"PLoS ONE"},{"issue":"9","key":"1792_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jacc.2008.02.088","volume":"52","author":"S Epelman","year":"2008","unstructured":"Epelman S, Tang WHW, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure. J Am Coll Cardiol. 2008;52(9):750\u20134. https:\/\/doi.org\/10.1016\/j.jacc.2008.02.088.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1792_CR17","doi-asserted-by":"publisher","first-page":"e0198144","DOI":"10.1371\/journal.pone.0198144","volume":"13","author":"J Ramchand","year":"2018","unstructured":"Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS ONE. 2018;13(6):e0198144. https:\/\/doi.org\/10.1371\/journal.pone.0198144.","journal-title":"PLoS ONE"},{"issue":"1","key":"1792_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11357-020-00300-2","volume":"43","author":"M Fagyas","year":"2021","unstructured":"Fagyas M, et al. Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19. GeroScience. 2021;43(1):19\u201329. https:\/\/doi.org\/10.1007\/s11357-020-00300-2.","journal-title":"GeroScience"},{"key":"1792_CR19","doi-asserted-by":"publisher","unstructured":"Walters TE, Kalman JM, Patel S.K, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace. 2016; euw246. https:\/\/doi.org\/10.1093\/europace\/euw246.","DOI":"10.1093\/europace\/euw246"},{"key":"1792_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.amjcard.2021.01.017","volume":"146","author":"A Hussain","year":"2021","unstructured":"Hussain A, et al. Soluble angiotensin-converting enzyme 2, cardiac biomarkers, structure, and function, and cardiovascular events (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2021;146:15\u201321. https:\/\/doi.org\/10.1016\/j.amjcard.2021.01.017.","journal-title":"Am J Cardiol"},{"key":"1792_CR21","doi-asserted-by":"publisher","first-page":"1182530","DOI":"10.3389\/fcvm.2023.1182530","volume":"10","author":"PN Cavalcante","year":"2023","unstructured":"Cavalcante PN, et al. B-type natriuretic peptide and N-terminal Pro-B-type natriuretic peptide in severe aortic stenosis: a comprehensive literature review. Front Cardiovasc Med. 2023;10:1182530. https:\/\/doi.org\/10.3389\/fcvm.2023.1182530.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"1792_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/1440-1681.12069","volume":"40","author":"SK Patel","year":"2013","unstructured":"Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in? Clin Exp Pharma Physio. 2013;40(8):551\u20139. https:\/\/doi.org\/10.1111\/1440-1681.12069.","journal-title":"Clin Exp Pharma Physio"},{"issue":"2","key":"1792_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jcmg.2018.11.026","volume":"12","author":"R Bing","year":"2019","unstructured":"Bing R, Cavalcante JL, Everett RJ, Clavel M-A, Newby DE, Dweck MR. Imaging and impact of myocardial fibrosis in aortic stenosis. JACC Cardiovasc Imaging. 2019;12(2):283\u201396. https:\/\/doi.org\/10.1016\/j.jcmg.2018.11.026.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"1792_CR24","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S0735-1097(01)01170-6","volume":"37","author":"J Fielitz","year":"2001","unstructured":"Fielitz J, et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol. 2001;37(5):1443\u20139. https:\/\/doi.org\/10.1016\/S0735-1097(01)01170-6.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1792_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jcmg.2019.09.005","volume":"13","author":"J Ramchand","year":"2020","unstructured":"Ramchand J, et al. Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis. JACC Cardiovasc Imaging. 2020;13(3):655\u201364. https:\/\/doi.org\/10.1016\/j.jcmg.2019.09.005.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"1792_CR26","doi-asserted-by":"publisher","first-page":"147032031666843","DOI":"10.1177\/1470320316668435","volume":"17","author":"K \u00dari","year":"2016","unstructured":"\u00dari K, et al. Circulating ACE2 activity correlates with cardiovascular disease development. J Renin Angiotensin Aldosterone Syst. 2016;17(4):1470320316668435. https:\/\/doi.org\/10.1177\/1470320316668435.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"9","key":"1792_CR27","doi-asserted-by":"publisher","first-page":"e033872","DOI":"10.1161\/JAHA.123.033872","volume":"13","author":"X Jacquemyn","year":"2024","unstructured":"Jacquemyn X, et al. Moderate aortic valve stenosis is associated with increased mortality rate and lifetime loss: systematic review and meta-analysis of reconstructed time-to-event data of 409 680 patients. JAHA. 2024;13(9):e033872. https:\/\/doi.org\/10.1161\/JAHA.123.033872.","journal-title":"JAHA"},{"issue":"21","key":"1792_CR28","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.jcin.2024.08.046","volume":"17","author":"A Maznyczka","year":"2024","unstructured":"Maznyczka A, et al. Timing of aortic valve intervention in the management of aortic stenosis. JACC Cardiovasc Intervent. 2024;17(21):2502\u201314. https:\/\/doi.org\/10.1016\/j.jcin.2024.08.046.","journal-title":"JACC Cardiovasc Intervent"},{"issue":"9","key":"1792_CR29","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3390\/jcm9092694","volume":"9","author":"JP Koerber","year":"2020","unstructured":"Koerber JP, Bennetts JS, Psaltis PJ. Early valve replacement for severe aortic valve disease: effect on mortality and clinical ramifications. JCM. 2020;9(9):2694. https:\/\/doi.org\/10.3390\/jcm9092694.","journal-title":"JCM"},{"issue":"9","key":"1792_CR30","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2666-7568(22)00188-X","volume":"3","author":"P Pibarot","year":"2022","unstructured":"Pibarot P, Clavel M-A. Live longer and better without aortic valve stenosis. Lancet Healthy Longevity. 2022;3(9):e573\u20134. https:\/\/doi.org\/10.1016\/S2666-7568(22)00188-X.","journal-title":"Lancet Healthy Longevity"},{"issue":"14","key":"1792_CR31","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jacc.2020.02.030","volume":"75","author":"J Bergler-Klein","year":"2020","unstructured":"Bergler-Klein J. NT-proBNP as a cornerstone for prognosis in valve disease. J Am Coll Cardiol. 2020;75(14):1673\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.030.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1792_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jacbts.2018.02.002","volume":"3","author":"M Gotzmann","year":"2018","unstructured":"Gotzmann M, et al. Alterations in titin properties and myocardial fibrosis correlate with clinical phenotypes in hemodynamic subgroups of severe aortic stenosis. JACC Basic Transl Sci. 2018;3(3):335\u201346. https:\/\/doi.org\/10.1016\/j.jacbts.2018.02.002.","journal-title":"JACC Basic Transl Sci"},{"issue":"7","key":"1792_CR33","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jacc.2014.11.047","volume":"65","author":"M-A Clavel","year":"2015","unstructured":"Clavel M-A, et al. Impact of classic and paradoxical low flow on survival after aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol. 2015;65(7):645\u201353. https:\/\/doi.org\/10.1016\/j.jacc.2014.11.047.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"1792_CR34","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1161\/CIRCULATIONAHA.112.001290","volume":"127","author":"HC Herrmann","year":"2013","unstructured":"Herrmann HC, et al. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a placement of aortic transcatheter valves (PARTNER) trial analysis. Circulation. 2013;127(23):2316\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.001290.","journal-title":"Circulation"},{"issue":"2","key":"1792_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.ajkd.2019.12.017","volume":"76","author":"TG Harrison","year":"2020","unstructured":"Harrison TG, et al. Association of NT-proBNP and BNP with future clinical outcomes in patients with ESKD: a systematic review and meta-analysis. Am J Kidney Dis. 2020;76(2):233\u201347. https:\/\/doi.org\/10.1053\/j.ajkd.2019.12.017.","journal-title":"Am J Kidney Dis"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01792-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01792-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:39:33Z","timestamp":1773049173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01792-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01792-6","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial ralationships that could be constructed as a potentional conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}